Safety Study of COVID19 Vaccine on the Market
Phase 4
Recruiting
- Conditions
- COVID-19
- Interventions
- Biological: Recombinant new coronavirus vaccine (CHO cell)
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 100000
- Registration Number
- NCT05890521
- Locations
- 🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
Not Applicable
Completed
- Conditions
- Coronavirus
- Interventions
- Biological: Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)Biological: Recombinant novel coronavirus protein vaccine (CHO cells)
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT05850507
- Locations
- 🇨🇳
Wannan Medical College Yijishan Hospital, Wuhu, Anhui, China
Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein
Phase 4
Active, not recruiting
- Conditions
- Latent Tuberculosis Infection
- Interventions
- Biological: Recombinant Mycobacterium tuberculosis fusion protein for injection
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 60500
- Registration Number
- NCT05746611
- Locations
- 🇨🇳
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Liuzhou, Guangxi, China
Clinical Trial of Mica
Phase 4
Active, not recruiting
- Conditions
- Latent Tuberculosis Infection
- Interventions
- Biological: Mycobacterium Vaccae for Injection
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 6800
- Registration Number
- NCT05680415
- Locations
- 🇨🇳
Liuzhou Center for Disease Control and Prevention, Liuzhou, Guangxi, China
🇨🇳Liujiang district Prevention and Control center, Liuzhou, Guangxi, China
Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine
Phase 3
Completed
- Conditions
- Prevention of Influenza
- Interventions
- Biological: Active compared VaccineBiological: Investigational Vaccine(0.5ml/vial)Biological: Investigational Vaccine(0.25ml/vial)
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 2550
- Registration Number
- NCT05642078
- Locations
- 🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
A Trial Evaluate the Immunogenicity and Safety of Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell)
Phase 3
Recruiting
- Conditions
- COVID-19
- Interventions
- Biological: Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)Biological: Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT05616754
- Locations
- 🇺🇿
Uzbekistan, Tashkent city, Said baraka street 10, Tashkent, Uzbekistan
Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)
Not Applicable
Completed
- Conditions
- COVID-19
- Interventions
- Biological: Inactivated COVID-19 vaccine (Vero Cell)Biological: Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 272
- Registration Number
- NCT05574985
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)
Phase 2
Suspended
- Conditions
- Tuberculosis
- Interventions
- Biological: Low-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)Biological: High-dose adjuvant for freeze-dried recombinant tuberculosis vaccine (AEC / BC02)Biological: High-dose freeze-dried recombinant tuberculosis vaccine (AEC / BC02)Biological: Lyophilized recombinant tuberculosis vaccine (AEC / BC02) placebo
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT05284812
- Locations
- 🇨🇳
Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China
Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac
Phase 1
Completed
- Conditions
- COVID-19
- Interventions
- Biological: Recombinant novel coronavirus vaccine (CHO cells)
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 480
- Registration Number
- NCT05205096
- Locations
- 🇨🇳
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of BBIBP-CorV
Phase 1
- Conditions
- COVID-19
- Interventions
- Biological: Recombinant novel coronavirus vaccine (CHO cells)
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 480
- Registration Number
- NCT05205083
- Locations
- 🇨🇳
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
© Copyright 2025. All Rights Reserved by MedPath